Influenza A virus is a pathogen of great medical impact. To develop novel antiviral strategies, it is essential to understand the molecular aspects of virus-host cell interactions in detail. During entry, the viral ribonucleoproteins (vRNPs) that carry the RNA genome must be released from the incoming particle before they can enter the nucleus for replication. The uncoating process is facilitated by histone deacetylase 6 (ref.
sequence motif close to the amino terminus of matrix protein (M1) exposed during acid priming of the viral core. It promotes the removal of M1 and induces disassembly of vRNP bundles. Next, the vRNPs interact with importin-α/β and enter the nucleus. Thus, influenza A virus uses dual importin-βs for distinct steps in host cell entry.
In the influenza A virus (IAV) particle, the eight single-stranded, negative-sense RNAs that make up the genome are individually packaged with a viral polymerase complex into helical viral ribonucleoproteins (vRNPs) in which the major protein is the nucleoprotein (NP). Together with the matrix protein, M1, the vRNPs form a stable, supra-macromolecular complex, the viral core, in which M1 provides a rigid shell around a bundle of vRNPs 3 . The uncoating process is initiated in early and maturing endosomes or macropinosomes after endocytosis of incoming virus particles 4, 5 . The M2 ion channel in the viral envelope allows exposure of the capsid to low pH and elevated K + levels, which results in loosening of interactions within the M1 core and between vRNPs in a process called priming 6 . Penetration of the primed core into the cytosol occurs by low pH-triggered, haemagglutinin-mediated membrane fusion in late endosomes [7] [8] [9] . In the cytosol, the M1 shell dissociates and vRNPs are imported into the nucleus [10] [11] [12] [13] [14] [15] . In the nucleus, the vRNPs are distributed as discrete complexes separated from each other 16 . Thus, IAV uncoating involves three major steps: priming, M1 shell disassembly and vRNP debundling.
We have previously shown that histone deacetylase 6 (HDAC6) serves as a key cellular factor in the M1 shell disassembly step 1 . It binds to unanchored ubiquitin chains and M1 exposed as viral cores emerge on the cytosolic surface of late endosomes. It connects the M1 shell to the cytoskeleton motors dynein and myosin II, which promote disassembly of the shell by a cytoskeleton-dependent mechanism related to aggresome processing. The vRNPs are released into the cytosol where importin-α /β (KPNA-KPNB1) mediate their nuclear uptake via nuclear pore complexes 1, 10, 17 .
To identify additional host proteins involved in the cytosolic uncoating and nuclear import steps, we performed an infection screen using a short interfering RNA (siRNA) library against 70 nuclear pore proteins and genes known to regulate nucleocytoplasmic transport [18] [19] [20] ( Fig. 1a and Supplementary Fig. 1 ). We found that infection was reduced in cells depleted of the nuclear import/export factors cellular apoptosis susceptibility protein (CAS; also known as XPO2 and exportin-2), KPNB1 and several nuclear pore proteins that have been previously identified as essential for infection 21 ( Supplementary Fig. 1 ). Among the novel hits, the nuclear import factor transportin 1 (TNPO1; also known as karyopherin-β 2 or Kapβ 2) caught our interest because it is a well-characterized receptor for nuclear import of cellular RNP complexes and RNA-binding proteins, such as heterogeneous nuclear RNP A1 (hnRNP A1) 22, 23 , many of which carry a recognition sequence termed PY-NLS (nuclear localization signal) 2, 24 . Depletion of TNPO1 using siRNA (TNPO1#2) or short hairpin RNA (shRNA) reduced the number of infected cells by 66-79% in A549 and Madin-Darby canine kidney (MDCK) cells (Fig. 1b-d) . Production of infectious virus was reduced by 81% in MDCK cells (Fig. 1e ). Infection could be rescued by expression of TNPO1 using an siRNA-insensitive construct (green fluorescent protein (GFP)-TNPO1; Fig. 1f ). TNPO1 was needed across various IAV strains: X31 (H3N2), WSN (H1N1) and Udorn (H3N2) of spherical and filamentous morphology (Fig. 1g) . Moreover, TNPO1 was required for X31 infection in HeLa cells ( Supplementary Fig. 2 ).
To define the virus entry step(s) that requires TNPO1, we first analysed the intracellular location of incoming M1 and vRNPs by indirect immunofluorescence (IIF) in control A549 cells at different times after virus internalization. At 3 h post-infection (h.p.i.), uncoating of the M1 shell had already occurred judging by the broad distribution of M1 throughout the cytoplasm (Fig. 2a) . At 4 h.p.i., NP staining occurred almost exclusively in the nucleus (Fig. 2b) . This indicated that, at 3-4 h.p.i., the majority of cores had lost their M1 shell and vRNPs had been released, debundled and nuclear imported.
That debundling of vRNPs could, at least in part, occur in the cytoplasm prior to nuclear import was shown by structured illumination microscopy (Fig. 2c) . Images taken 1 h after synchronized release of vRNPs from late endosomes in mouse embryonic fibroblasts (MEFs) showed that, in addition to large bright spots containing NP, smaller uniform NP-containing spots of low brightness were present in the cytoplasm. That these were similar in brightness and size to the spots in the nucleus known to represent individual Letters NATuRe MIcRobIoLogY vRNPs 16, 25 suggested that debundling of vRNPs can and does take place in the cytoplasm.
In TNPO1-depleted cells, M1 was present in bright, cytoplasmic spots. The majority of NP also remained in cytoplasmic spots that had a distribution similar to viruses trapped by bafilomycin A1 treatment in endosomes (Fig. 2b) . Thus, M1 uncoating, vRNP debundling and vRNP nuclear import were all inhibited in cells depleted of TNPO1.
Triple-staining of TNPO1-depleted and KPNB1-depleted cells 2.5 h.p.i. provided evidence for a previously undetected step in the uncoating process; the release of uncoated or partially coated cores from late endosomes into the cytosol (Fig. 2d-g ). KPNB1   TPR  NUP205  CAS  NUP160  NUTF2  NUP214  LOC646565  SEC13  TNPO1  RANBP2  NUP107  IPO8  RANBP1  NUPL1  NUP188  RAE1 19 hit genes (out of 70) from the nucleocytoplasmic transport factor siRNA screen. The screen was repeated independently three times using the IAV X31 strain in A549 cells. The readout for infection was done by IIF against NP (HB-65). The average (Ave.) infection inhibition of individual siRNAs and that of the three independent siRNAs are shown. b, IAV infection is reduced in TNPO1-depleted cells. A549 cells treated with AllStars Negative Control siRNA or with siTNPO1 or siATP6V1B2 (a vacuolar-ATPase subunit, used as a positive control) were infected with IAV and stained for NP (HB-65) at 10 h.p.i. Scale bars, 200 µ m. Nuclei were stained with DAPI. The experiments were repeated independently multiple times (n > 3) with similar results. c, Reduced IAV infection in A549 cells transfected with siTNPO1#2 or siATP6V1B2. TNPO1 depletion was confirmed by western blotting. n = 3 biologically independent experiments. The P value was determined using two-sided, unpaired t-test. d, Reduced IAV infection in MDCK cells expressing TNPO1 shRNA. TNPO1 depletion was confirmed by western blotting. n = 4 biologically independent experiments. The P value was determined using two-sided, unpaired t-test. e, Reduced IAV replication in TNPO1-depleted MDCK cells. Three days after TNPO1 shRNA induction by doxycycline, the cells were infected with X31 (MOI = 0.01) after which the supernatant was harvested at 24 h.p.i. and the IAV titre was determined by the TCID 50 assay. n = 3 biologically independent experiments. f, IAV infection is rescued in TNPO1-depleted A549 cells by an siTNPO1-insensitive construct expressing GFP-TNPO1. n = 3 biologically independent experiments. g, TNPO1 is required for infection of multiple IAV strains in A549 cells. siRNA-treated cells were infected with X31 (H3N2), WSN (H1N1) and Udorn (H3N2) strains. siATP6V1B2 was used as a positive control. n = 3 biologically independent experiments. All bar graphs show the mean ± s.d. The dotted lines in c,d,f,g indicate 50% infection compared to the control. The rank-weighted colocalization index of M1 and NP spots, excluding LAMP1 and the nucleus, is shown. n = 2 independent experiments. f, The cytoplasmic NP area is increased in TNPO1-depleted cells. IAV-infected A549 cells (n = 15) at 2 and 2.5 h.p.i. were processed as in e. n = 2 independent experiments gave similar results. The mean ± s.d. is shown. g, Cytoplasmic M1 intensity is increased in TNPO1-depleted cells. IAV-infected A549 cells (n = 15) at 2 and 2.5 h.p.i. were processed as in e. The experiments were repeated independently twice with similar results. The mean with 95% CI is shown. The P value was determined using two-sided, unpaired t-test. h, TNPO1 promotes M1 bypass uncoating. A549 cells were subjected to acid bypass fusion/hemifusion, M1 uncoating and vRNP import assays. The percentage of cells positive for DiOC18(3), dispersed M1 (HB-64) staining and nuclear NP was quantified for the fusion assay, the M1 uncoating assay and the vRNP import assay, respectively. The mean ± s.d. is shown (n = 3). i, Acid bypass IAV fusion/hemifusion is unaffected in TNPO1-depleted MDCK cells. Bypass (− )/(+ ) indicates pH 6.8-treated or pH 5.0-treated samples, respectively. This experiment was performed 3 days after shRNA induction. The mean is shown (n = 2). j, Acid bypass M1 uncoating is blocked in TNPO1-depleted MDCK cells. The mean ± s.d. is shown (n = 5). k, Ectopic expression of GFP-human TNPO1 rescues acid bypass M1 uncoating in TNPO1-depleted MDCK cells. After 2 days of shRNA induction, cells were transfected with GFP or GFP-TNPO1 and subjected to the acid bypass M1-uncoating assay 20 h later. The mean ± s.d. is shown (n = 3). The P value was determined using two-sided, unpaired t-test. The dotted lines in h indicate 50% and 100% infection compared to the control; the dotted lines in i-k indicate 50% infection compared to the control. 
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In TNPO1-depleted cells at this time point, NP staining was mainly cytoplasmic and present in spots of medium brightness that contained variable amounts of M1. Many of these spots did not colocalize with lysosome-associated membrane glycoprotein 1 (LAMP1), a marker for endolysosomes (Fig. 2d) . In KPNB1-depleted cells, NP-positive spots of different brightness were also distributed throughout the cytosol and they did not colocalize with LAMP1. When cores were synchronously released from late endosomes in TNPO1-depleted cells 1 and analysed after 30 min, many of the cytoplasmic NP spots contained M1 in contrast to control cells that displayed small NP spots in the nucleus or larger spots in the cytoplasm devoid of M1 ( Supplementary Fig. 3 ). Taken together, these results indicated that TNPO1 is required for a step involving the removal of M1 from cores that have been released into the cytosol.
Judging by the brightness of the NP-positive spots in TNPO1-depleted cells compared to nuclear vRNPs in control cells, the vRNPs were still associated with each other. When KPNB1 was depleted, vRNPs failed to enter the nucleus 15, 16, 21 , but uncoating of cytoplasmic cores proceeded further than in TNPO1-depleted cells; M1 was no longer associated with NP-containing spots (Fig. 2d) . The smaller spot size indicated that vRNPs had been debundled ( Fig. 2d,f) . Taken together, these results indicated that TNPO1 removed M1 from incoming cores and debundled the vRNPs in the cytosol. Although KPNB1 is clearly essential for nuclear import 16, 21 , it was dispensable for core uncoating and debundling.
Next, we used synchronized penetration of cores into the cytosol of A549 cells by inducing fusion of pre-primed, cell surface-bound viruses with the plasma membrane (acid bypass) 6, 26 ( Supplementary  Fig. 4a ). Fusion/hemifusion was confirmed by lipid mixing 25 . Depletion of TNPO1 and KPNB1 inhibited vRNP import by 68% and 79%, respectively ( Fig. 2h and Supplementary Fig. 4b ). In half of the TNPO1-depleted cells, M1 uncoating failed to occur ( Fig. 2h and Supplementary Fig. 4a ). In TNPO1-depleted MDCK cells, M1 uncoating was reduced by 75% compared to control cells, but fusion/hemifusion was unaffected (Fig. 2i,j) . M1 uncoating could be rescued by ectopic expression of shRNA-insensitive GFPhuman TNPO1 (Fig. 2k) . Taken together, these findings confirmed that TNPO1 was involved in the dissociation of M1 from incoming cores, whereas KPNB1 nuclear imported vRNPs 21 . In further support of a role for TNPO1 in M1 uncoating, overexpression of TNPO1 increased M1 uncoating ( Supplementary Fig. 4c ), and that of a recombinant protein carrying the hnRNP A1 M9-NLS 22, 23 caused a reduction ( Supplementary Fig. 4c ). We concluded that the role of TNPO1 in the dissociation of M1 from incoming cores was associated with the PY-NLS-binding function.
IIF showed that TNPO1 in control cells is localized in the nucleus with a few spots in the cytoplasm (Fig. 3a) . Fifteen min after synchronous release of particles from late endosomes in MEFs 1 , we could observe that some of the NP-containing spots in the cytoplasm contained TNPO1 (Fig. 3a , wild type (WT)). Spots were also weakly stained for M1. This indicated that TNPO1 associates with incoming cores and with vRNP bundles that have residual M1. That TNPO1 also colocalized with M1/NP-positive spots in HDAC6 −/− MEFs (Fig. 3a, HDAC6 −/− ) indicated that TNPO1 association with cores takes place in the absence of HDAC6 and aggresome processing. In these spots, the staining for M1 was stronger, suggesting that TNPO1 can bind to more intact-looking cores but is unable to remove M1 efficiently without HDAC6 action.
When virus was primed at pH 5.6 and 120 mM KCl, lysed and incubated with His-TNPO1 for pull-down, M1 was found to coprecipitate (Fig. 3b) . However, only trace amounts were precipitated from lysates prepared from unprimed virus. When cells were infected for 2.5 h in the presence or absence of NH 4 Cl, M1 coprecipitated less efficiently with TNPO1 in the NH 4 Cl-treated cells than in the non-treated cells ( Supplementary Fig. 5a ,b).
When examining the amino acid sequence of M1, we observed short sequences close to the amino terminus that resemble known elements to the PY-NLSs recognized by TNPO1 in cellular substrates 27 . These elements are referred to as epitopes 1, 2 and 3 ( Fig. 3c) , of which the glycine residue in epitope 1 is critical for TNPO1 recognition 2 . Sequences similar to epitopes 1 and 2 are conserved among M1 of IAV strains. The crystal structure of M1 (ref. 28 ) shows that they are on the surface of M1. We hypothesized that, in primed cores, they may serve as a binding motif for TNPO1. The hypothesis was tested by generating a mutant IAV WSN (H1N1) strain in which Gly 18 in M1 was replaced with alanine by reverse genetics 29 . When normalized for the same number of viruses, the G18A mutant virus reached 2% of the infectivity observed for the WT virus (Fig. 3d) .
When His-TNPO1 was pulled-down after incubation with preprimed virus lysates containing either the G18A virus or the WT control virus, the M1 of G18A precipitated less efficiently (Fig. 3e) . This indicated that Gly 18 is essential not only for infection but also for efficient TNPO1 association. We also found that Gly 18 is an epitope of the HB-64 monoclonal antibody used to detect M1 uncoating ( Supplementary Fig. 6 ), indicating that acidification exposes the PY-NLS.
We solved the crystal structure of the neutral pH form of M1 with the G18A mutation expressed in Escherichia coli, and compared it to the structure of the WT protein. The main difference between the WT structure was seen around the PY-NLS sequence motif. A cavity formed by loops L1 (15) (16) (17) (18) (19) and L3 (49-53) in WT M1 was absent in G18A ( Fig. 3f-h, Supplementary Fig. 7a and Supplementary Table 1 ). The 1.9-Å resolution G18A M1 N-terminal domain structure, although monomeric in solution, forms the so-called face-to-back dimer in the crystal lattice, representing the neutral pH oligomeric state of M1 similar to Protein Data Bank entries 1EA3 or 5V8A 30, 31 ( Supplementary Fig. 7b ). Gly 18 and surrounding amino acid residues are masked in this face-to-back M1-M1 interface crystallized at neutral pH, but are exposed in acidified M1 crystals 28 ( Supplementary Fig. 7c ). This may explain why M1 in lysates of primed viruses engage TNPO1 better than unprimed viruses (Fig. 3b) . During virus entry, priming may thus allow subsequent TNPO1 binding to M1. It may explain why unprimed viruses are not uncoated 6 and why TNPO1 does not interfere with the functions of newly synthesised M1 in infected cells.
In summary, our results lead to a more detailed step-by-step model for IAV uncoating (Fig. 4) . After viral uptake into endosomes, the M2 cation channels open, resulting in an influx of protons and K + ions that loosens interactions, stabilizing the core 6 , and triggers a conformational change in M1 that exposes the PY-NLS close to the N terminus. Following viral fusion in late endosomes, the core is exposed to cytosolic factors. HDAC6 binds to shellassociated, unanchored ubiquitin chains 1 . Together with other components of the aggresome-processing machinery, HDAC6 releases the shell from the endosome surface and ruptures it. This process depends on forces generated by microtubules and microfilaments and the corresponding motors, dynein and myosin II. At the same time, TNPO1 associates with the PY-NLS exposed in the primed M1. The main role of TNPO1 is to promote the removal of vRNPassociated M1, which allows dissociation of vRNPs from each other. Some of the removed M1 may enter the nucleus with TNPO1. KPNA and KPNB1 bind to the classical NLS in NP, resulting in the nuclear import of fully or partially debundled vRNPs. Thus, the primary role of TNPO1 is M1 removal and debundling of vRNPs in the cytosol.
Methods
Cells. A549, MDCK, HEK293T and HeLa cells were obtained from the American Type Culture Collection (ATCC). MEFs were isolated from embryonic day 13.5 from male embryos of WT and HDAC6
−/− mice 32 . For some acid-bypass experiments, the plate wells were coated with 0.01% poly-l-lysine before use. All ) and subjected to a His-TNPO1 pull-down assay, analysed by SDS-PAGE and western blotting. His-MBP was used as a negative control. n = 3 independent experiments gave similar results. IP, immunoprecipitation. c, Sequence alignment of known PY-NLSs with the conserved IAV M1 N-terminal sequence. Sequences for epitopes 1 (a hydrophobic patch, containing glycine (highlighted in light pink), 2 (a basic patch) and 3 (PY) were adapted from refs. 2, 27 ) . FUS, fused in sarcoma. d, Gly 18 is critical for IAV infection. IAV WSN strains (WT or G18A) were reverse-genetically produced to infect A549 cells. Their infectivity was analysed by IIF against NP (HB-65). The mean ± s.d. is shown (n = 3). The P value was determined using two-sided, unpaired t-test. e, TNPO1 coprecipitates less efficiently with M1 from the G18A virus than from the WT virus. Viruses were primed and precipitated with His-TNPO1 as in b and detected by SDS-PAGE and western blotting. n = 2 independent experiments gave similar results. mAb, monoclonal antibody. f, Structure of G18A compared to WT M1-N (L1/L3 loops). Superposition of M1-N structures present in the Protein Data Bank that crystallized in the neutral pH face-toback arrangement. G18A M1-N is shown as a grey cartoon with selected residues as sticks in atom colours. Protein Data Bank entries 1EA3 (ref. 30 ) and 5V8A 31 are shown as cartoon models in blue and gold, respectively, with selected residues displayed as lines. g, Detailed view of the G18A mutation with its electron density. The L1/L3 loops of G18A M1-N are shown as sticks in grey and atom colours. A sigma A-weighted (2mF o -DF c ) simulated annealing omit electron density map is displayed in blue (1σ ). h, Surface representation of the L1-L3 region of M1-N, highlighting the closing of a surface cavity in M1-N G18A (grey, left) when compared with 1EA3 (blue, right).
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NATuRe MIcRobIoLogY cells were maintained in DMEM (Invitrogen), supplemented with 10% FCS under 5% CO 2 at 37 °C. MDCK cells capable of inducible expression of shRNA targeting the canine TNPO1 sequence GCAGTGCCTTTGCTACCTTAG was a kind gift from B. L. Margolis (University of Michigan) 33 .
Viruses. IAV X31 strain (an H3N2 reassorted strain derived from PR8 and A/Hong Kong/1/68 strains) was purchased from Virapur. To propagate the X31 virus, 60 pathogen-free chicken eggs were inoculated with the virus and incubated at 33-37 °C for 2 days. The allantoic fluid was harvested and clarified by lowspeed centrifugation, which was then concentrated by high-speed centrifugation.
To further concentrate the virus, two rounds of 10-40% sucrose gradient centrifugation were performed, viral bands harvested, pooled and re-suspended in formulation buffer (40% sucrose, 0.02% BSA, 20 mM HEPES, pH 7.4, 100 mM NaCl and 2 mM MgCl 2 ). The viral titre was determined as 1.0 × 10 10 TCID 50 (median tissue culture infectious dose) infectious units per ml in MDCK cells. The virus was aliquoted and stored in formulation buffer at − 80 °C until use. The IAV WSN (A/WSN/1933) (H1N1) strain was propagated in MDCK cells and purified by sucrose gradient ultracentrifugation as previously described 6 . The IAV Udorn (A/Udorn/72) (H3N2) strain was a kind gift from J. Pavlovic (University of Zurich). TCID 50 assays were performed as described elsewhere.
Reagents. Hybridoma cell lines producing monoclonal antibodies against IAV M1 anti-M1 (HB-64) and NP (HB-65) were purchased from the ATCC. Anti-IAV M1 (goat, 1311) was purchased from Virostat. Anti-TNPO1 (mouse, ab10303), anti-TNPO1 (rabbit, ab191539) and anti-LAMP1 (rabbit, ab24170) antibodies were purchased from abcam, and anti-CAS (sc-1708) was from Santa Cruz. Anti-KPNB1 (clone 31H4) monoclonal antibody was purchased from Sigma-Aldrich, anti-His monoclonal antibody from Sigma-Aldrich and anti-GFP monoclonal antibody (JL-8) from Clontech. The mouse monoclonal anti-A/WSN/33 haemagglutinin (clone H15-B9-22; The Wistar Institute, Philadelphia, PA, USA) 34 was a kind gift from S. Stertz (University of Zurich). The anti-IAV M1/M2 monoclonal antibody (E10) was a kind gift from J. Pavlovic. Lipofectamine RNAiMax, Lipofectamine 2000 or 3000 and OPTI-MEM were purchased from Invitrogen. Bafilomycin A1, cycloheximide, doxycycline, imidazole, TPCK-trypsin, 0.1% poly-l-lysine and fibronectin were purchased from Sigma-Aldrich. Ni-NTA agarose resin was purchased from Qiagen. µ CLEAR 96-well optical microplates plates (655090) were purchased from Greiner Bio-one.
IAV reverse genetics.
Reverse genetics using the eight plasmid rescue system 29 (a kind of gift of R. Webster, St Jude Children's Research Hospital) was performed as follows: per 60-mm dish of HEK293T cells, 1 µ g each of purified plasmid DNA (that is, pHW-2000-M, -NP, -HA, -NA, -PB1, -PB2, -PA and -NS1 (WSN)) were co-transfected using Lipofectamine 2000. Eighteen hours later, the medium was exchanged to DMEM containing 0.2% BSA, 0.1% FCS, 2 mM l-glutamine and 1 µ g ml −1 TPCK-trypsin. Virion-containing supernatants were harvested at 48 h post-transfection. The mutant virus and the corresponding WT virus were recovered in the medium of the transfected cells and quantitated using an IIF-based cell-binding assay. siRNA transfections. siRNAs (AllStars Negative Control, TNPO1#1 (Hs_TNPO1_7:CAGCATGTTAAGCCTTGTATA), TNPO1#2 (Hs_TNPO1_2:CAGAATTGGCCTGACCTCTTA), TNPO1#3 (Hs_TNPO1_6:CTGGAACAACTTAATCAGTAT), Hs_ ATP6V1B2_3 (CACGGTTAATGAAGTCTGCTA) and Hs_KPNB1_1 (TCGGTTATATTTGCCAAGATA) were purchased from Qiagen. Reverse transfection was done using Lipofectamine RNAiMax and OPTI-MEM at a final 10 nM siRNA concentration. The cells were maintained in a 5% CO 2 incubator at 37 °C for 3 days before experiments were performed. RNA interference screening. Seventy host genes regulating nucleocytoplasmic transport (3 siRNAs per gene) were distributed across 4 plates in a 96-well plate format. siRNAs (10 µ l of a 100 nM stock in OPTI-MEM; Invitrogen) were added to the transfection reagent (0.1 µ l RNAiMax in 20 µ l OPTI-MEM) in wells of 96-well plates and incubated at room temperature for 45 min. Then, 1,500 A549 cells were added to each well in 70 µ l of growth medium. Sixty-two hours after transfection, cells were infected with multiplicity of infection (MOI) of 0.2-0.5 of IAV X31 in infection medium for 10 h. Cells were fixed with 4% formaldehyde in PBS, stained for NP, and DNA was stained with 4,6-diamidino-2-phenylindole (DAPI). Cells were automatically imaged using a × 20 objective on a BD pathway 855 microscope. The percentage of infected cells was analysed by the Infection Counter, a MATLAB-based program, as previously described 25 . The Allstars Negative Control was included three times on each plate. All siRNAs used for screening were designed by and purchased from Qiagen.
IAV entry, infection and replication assays. Virus assays were performed in infection medium (DMEM, 50 mM HEPES buffer, pH 6.8, and 0.2% BSA). The virus entry assays were carried out as per the protocols previously described 1, 25 . The detection time point for infection (NP expression) was 7 h.p.i. The assays were performed either in 24-well plates for confocal imaging (using × 100 and × 63 objectives) and FACS analysis or 96-well optical bottom plates for automated imaging. For assays using MEFs, the surface of plates or coverslips was coated 
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with fibronectin (50 μ g ml −1 in PBS) for 30 min prior to the experiment. Coverslips were mounted on slides with Immu-Mount (Thermo Fisher Scientific). For rescue experiments using A549 cells, siRNA TNPO1#2 was transfected using RNAiMax. Two days later, an siRNA-resistant construct, pEGFP-TNPO1, was transfected using Lipofectamine 2000. Eighteen hours later, the infection assay was performed and cells were fixed at 6.5 h.p.i., stained for NP and analysed by FACS. The proportion of NP-positive cells in the low-to-mid-GFP-expressing population was analysed using the FlowJo software. High GFP-expressing cells were not analysed. For IAV replication assays, MDCK cells were induced for TNPO1 shRNA expression by the addition of 1 µ g ml −1 doxycycline to the growth medium for 3 days. IAV X31 was then infected at MOI = 0.01 for 1 h, after which the medium was replaced with MEM supplemented with 0.1% FCS, 0.2% BSA, 100 U ml −1 penicillin, 100 µ g ml −1 streptomycin, 2 mM l-glutamine and 1 µ g ml −1 TPCKtrypsin. Supernatants were harvested at 24 h.p.i. (and 48 h.p.i.) and the infectious titre was analysed by TCID 50 on MDCK cells.
Synchronized penetration assay at late endosomes (NH 4 Cl washout).
Cells grown on coverslips in 24-well or 4-well plates were bound with 1 µ l X31 (MOI of ~100) per well in infection medium for 1 h on ice. The cells were washed and warmed to 37 °C to allow endocytosis for 20 min in the presence of 1 mM cycloheximide, after which the medium was replaced with STOP medium (DMEM, 50 mM HEPES, pH adjusted to 7.4, supplemented with 20 mM NH 4 Cl immediately before use) and incubated further for 1 h to accumulate virus particles in the late endosomes. The medium was replaced with infection medium with cycloheximide to allow endosomal re-acidification and viral penetration, and cells were fixed at indicated time points and processed for IIF 1, 35 .
Synchronized fusion assay at the plasma membrane (acid bypass). Labelling of the virus with lipophilic fluorescent dyes (R18/SP-DiOC18(3)) was done as previously described 1, 25 . In brief, 50 μ l X31 stock was diluted in 750 μ l PBS, to which a premixture of R18 and SP-DiOC18(3) was added with vigorous mixing, at a final concentration of 0.4 μ M and 0.2 μ M, respectively. The mixture was rocked for 1 h at room temperature in the dark and filtered through a syringe filter with a 0.22-μ m pore size (Millipore) to remove unbound dye and aggregates. Cells were trypsinized, counted and 50,000 cells were taken into each eppendorf tube in a volume of 50 μ l. R18/SP-DiOC18(3)-labelled virus (50 μ l) was added and the mixture was incubated on ice for 30 min with tapping every 10 min to allow for virus binding to cells. Cells were washed with cold infection medium by lowspeed centrifugation to remove unbound virus particles. After the removal of the supernatant, 300 μ l pre-warmed pH 7.4 medium or medium buffered to pH 5.0 with 50 mM citrate buffer were added to the cells, mixed and incubated at 37 °C in a water bath with circulation in a floating device. After 2 min, cells were fixed immediately by direct addition of 300 μ l of 8% formaldehyde in PBS. After washing, the cells were resuspended in 250 μ l FACS buffer and analysed by FACS.
Acid bypass M1 uncoating and vRNP nuclear import assays. To detect M1 uncoating and NP expression by inducing viral fusion at the plasma membrane, acid-bypass uncoating and infection assays were performed as previously described 1 . X31 stock (5 μ l, MOI of ~500 for the uncoating assay and 2 μ l, MOI of ~200 for the nuclear import assay/well of a 96-well optical plate) was pre-bound to cells on ice for 1 h. Cells were washed with cold infection medium to remove unbound virus. After the removal of infection medium, 500 μ l pre-warmed pH 6.8 medium or medium buffered to pH 5.0 with citrate buffer were added. The plates were incubated in a 37 °C water bath on top of a metal block touching the plate bottom directly. After 2 min, the cells were washed twice with cold infection medium and incubated with STOP medium. Cells were further incubated at 37 °C for 3 min for the M1-uncoating assay or for 45 min for the nuclear import assay, on a pre-warmed metal plate in 5% CO 2 at 37 °C, after which they were fixed and processed for confocal microscopy. M1 uncoating was detected by the characteristic increase in the immunostaining with anti-M1 monoclonal antibody (HB-64) after uncoating. For M1-uncoating rescue assays in TNPO1 shRNAexpressing MDCK cells, the pEGFP-TNPO1 or pEGFP-C3 (control) constructs were transfected 2 days after shRNA induction by doxycycline. Twenty hours after transfection, cells were trypsinized, counted and 30,000 cells were taken in each eppendorf tube in a volume of 50 μ l. Three μ l (MOI of ~100) of X31 in 50 μ l infection medium was added to the cells, mixed and incubated on ice for 30 min with occasional tapping. Cells were washed with cold infection medium by lowspeed centrifugation to remove unbound virus particles. After the removal of the supernatant, 300 μ l pre-warmed pH 6.8 medium or medium buffered to pH 5.0 with 50 mM citrate buffer were added to the cells and incubated at 37 °C for 2 min in a water bath with circulation on a floating device. Furthermore, 300 µ l prewarmed pH 6.8 medium or pH 8 medium (to re-neutralize the pH 5.0 medium) were added and incubated for 3 min at 37 °C. Cells were fixed by directly adding 600 μ l of 8% formaldehyde in PBS. After washing, the cells were resuspended in 250 μ l FACS buffer, stained with HB-64 (1:3,000) and analysed by FACS.
Recombinant protein purification. His-tagged human TNPO1 was expressed at 21 °C in SG13 bacterial cells. The cell pellet was lysed by French Press twice and incubated with Ni-NTA agarose for 2 h at 4 °C 36 . The purified protein was eluted with imidazole-containing buffer (50 mM Na 2 HPO 4, 250 mM NaCl, 400 mM imidazole and 5 mM β -EtSH) followed by gel filtration in gel-filtration buffer (10 mM HEPES, pH 7.5, 150 mM NaCl and 1 mM dithiothreitol) with a Superdex 200 10/300 GL column (GE Healthcare). His-tagged maltose-binding protein (MBP) proteins were purified from pOPINM-HisMBP-mouse HDAC6 constructs. Mouse HDAC6 proteins were expressed in Sf9 insect cells and purified with Ni-NTA agarose (Qiagen) and gel filtration with a Superdex 200 16/60 column. Purified protein was digested with 3C protease (Sigma-Aldrich) overnight on ice, then purified with amylose resin (NEB). After the 3C cleavage step, His-tagged MBP was eluted from the resin with 10 mM maltose-containing buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10 mM maltose and 2 mM TCEP) and gel filtrated in gel-filtration buffer (20 mM Tris, pH 7.5, 200 mM NaCl and 2 mM TCEP).
Pull-down assay from purified IAV extracts. Purified IAV X31 was treated with or without priming for 30 min at 37 °C using either neutral buffer (30 mM HEPES and 30 mM MES, pH 7) or priming buffer (30 mM MES, pH 5.6, and 120 mM KCl) 6 . After priming, IAV was lysed with CSK buffer (10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA and 0.1% Triton X-100) supplemented with a protease inhibitor cocktail (Roche). Lysis was performed by incubating for 30 min on ice with occasional pipetting. The lysed virus was used for the Ni-NTA agarose pull-down analysis. Purified His-tagged human TNPO1 protein (4 µ g) was mixed with the virus lysate. Purified His-tagged MBP was used as a negative control. The mixture was incubated for 3 h at 4 °C on a rotary shaker, after which 20 µ l of a 50% slurry of Ni-NTA agarose beads (equilibrated with CSK buffer containing 20 mM imidazole and 1% BSA) were added and rotated for 30 min at 4 °C. The samples were spun down at 3,0000 r.p.m. for 1 min at 4 °C, beads were washed once with CSK buffer containing 20 mM imidazole and 1% BSA, followed by two washes in CSK buffer containing 20 mM imidazole. Finally, the precipitate was eluted with 15 µ l CSK buffer containing 200 mM imidazole. The samples were lysed in Laemmli buffer, boiled for 5 min at 95 °C, loaded onto a Bolt 4-12% Bis-Tris Plus Gel (Thermo Fisher Scientific) and run in MES running buffer for 35 min at 200 V. The protein samples were transferred onto immobilon-P PVDF (polyvinylidene difluoride) membranes (Merck) using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad), according to the instructions by the manufacturer. After transfer, the PVDF membrane was washed for 5 min in 1× TBST buffer, then blocked with 5% skimmed milk (Sigma) in 1× TBS buffer for 1 h at room temperature. Primary antibodies against M1 (HB-64) and/or Histag were used at 1:3,000 and 1:1,000 dilution, respectively. The primary antibody reaction was carried out at 4 °C overnight, then the membrane was washed three times with 1× TBST buffer for 5 min each. Secondary antibodies (anti-mouse IgG-horseradish peroxidase conjugated or anti-goat IgG-horseradish peroxidase conjugated) were used at 1:3,000 dilution in 5% skimmed milk in 1× TBS buffer and incubated for 1 h at room temperature and washed with 1× TBST buffer three times for 15 min each. The signal was detected using SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific), exposed on an X-ray film (Fuji Film) and developed with a developer machine.
Immunoprecipitation assay. A549 cells growing in 60-mm dishes were washed with infection medium and bound with 10 µ l (MOI of ~50) of X31 for 45 min on ice. The cells were washed and incubated in warm infection medium or STOP medium at 37 °C for 2.5 h, after which the cells were washed in PBS, harvested with a cell scraper and centrifuged at 3,000 r.p.m. for 5 min using a benchtop microcentrifuge. The supernatant was removed and the cell pellet was lysed in 100 µ l CSK buffer, sonicated and incubated for 60 min on ice with occasional vortexing. The lysate was centrifuged at 3,000 r.p.m. for 5 min, after which the supernatant was reacted with anti-TNPO1 antibody (mouse, 1 µ g) or mouse IgG (1 µ g) and rotated for 2 h at 4 °C. Then, 20 µ l of a 1:1 slurry of Protein A/G Agarose (Pierce) in CSK buffer were added and rotated for 1 h at 4 °C. The beads were washed three times in CSK buffer by pelleting at 3,000 r.p.m. for 5 min at 4 °C and processed for SDS-PAGE and western blotting as described for the pull-down assay.
Molecular cloning.
Plasmid constructs used were pEGFP-M9NLS, pEGFP-M9NLS mutant and pQE-Trn1 (ref. 36 ). pEGFP-TNPO1 was a kind gift of W.-Y. Tarn (Academia Sinica, Taiwan). To generate the TNPO1#2-resistant construct pEGFP-TNPO1-Res1, a primer (GCAACAAAAACTGGAACAACTGAATCAGTATCCAGAC) was used to introduce a silent point mutation into the pEGFP-TNPO1 sequence by mutagenesis PCR. GFP-M1 was constructed by inserting the IAV (A/WSN/1933(H1N1) M1 WT sequence amplified by PCR using the primer pair (forward: CGCCTCGAGATGAGTCTTCTAACCGAGGTCGAA, reverse: GGAATTCTCACTTGAATCGTTGCATCTGC), into the pEGFP-C3 vector via XhoI/EcoRI restriction sites. The point mutations G18A, P19A, L20A and K21A were further introduced using the GFP-M1 as template. The primers used for each point mutant were G18A (forward: GTCCCGTCAGcCCCCCT, reverse: GATAGAGAGAACGTACGTTTCGACCTC), P19A (forward: CCCGTCAGGCgCCCTCAAAGC, reverse: ACGATAGAGAGAACGTACGTTTCGACCTC), L20A (forward: GTCAGGCCCCgcCAAAGCCGAG, reverse: GGGACGATAGAGAGAACGTACGTTTCGACC) and K21A (forward: GGCCCCCTCgcAGCCGAGATCG, reverse: Letters NATuRe MIcRobIoLogY TGACGGGACGATAGAGAGAACGTACGTTTC). All constructs were verified by sequencing.
Cloning, expression and purification of G18A M1-N. A DNA template encoding matrix protein M1 from IAV A/WSN/1933(H1N1) (GenBank accession number: CY034133.1) was gene synthesized by GeneArt. The G18A M1 1-158 (G18A M1-N) sequence was generated by PCR and cloned into pOPINF using In-Fusion cloning 37 . This construct, pOPINF G18A M1-N, yields an N-terminal His× 6 tag with a 3C protease site followed by the M1-N sequence that corresponds to Uniprot P05777, except for the single point mutation G18A. Protein expression was performed in E. coli BL21 DE3 cells via autoinduction at 20 °C. Cell extracts were obtained using an EmulsiFlex-C3 (Avestin) cell disruptor and clarified via centrifugation and filtration. The target protein was first purified over nickel Superflow (Qiagen) resin followed by gel filtration on a S75 HiLoad 16/60 column (GE Healthcare). His-tagged G18A M1-N protein was concentrated to 9.1 mg ml −1 in 20 mM Tris, pH 7.5, 200 mM NaCl, 2 mM TCEP and 0.02% NaN 3 .
Crystallization, data collection and structure determination. N-terminally His-tagged IAV M1 protein consisting of residues 1-158 (M1-N) was crystallised using the sitting-drop vapour diffusion method at 20 °C with a Phoenix nanolitre dispensing robot (Art Robbins). M1-N protein (100 nl) at 9.1 mg ml −1 in protein buffer (0.02 M Tris, pH 7.5, 0.2 M NaCl, 2 mM TCEP and 0.02% NaN 3 ) was mixed with 100 nl crystallization buffer (30% (w/v) EDO_P8K, 0.1 M MB2, pH 7.5, and 10% NPS; Molecular Dimensions Morpheus HT-96 C6). Long rod-like crystals were obtained after 5-10 days, which were harvested and cryo-cooled in liquid nitrogen. X-ray data collection was carried out at the SLS PX-II beamline in Villigen, Switzerland, at 100 K. IAV M1-N protein crystals were diffracted to 1.9 Å and belonged to space group P1 at pH 7.5 with two molecules per unit cell. Diffraction data were integrated and scaled using the XDS program package 38 and the M1-N structure was solved by the molecular replacement method with PHASER 39 using available WT M1 structures as search models. The structure was then manually completed and further improved by the crystallographic-simulated annealing routine followed by individual B-factor refinement in PHENIX 40 . The structure was finalized by several rounds of manual rebuilding in COOT and refinement in BUSTER 41 . Structure validation was carried out using tools implemented in COOT. Structural images for figures were prepared with PyMOL (https://pymol.org). Atomic coordinates and structure factors have been deposited in the Protein Data Bank under accession code 6I3H.
Image acquisition. For the initial RNA interference screening, automated image acquisition was performed using 96-well optical bottom plates with a BD Pathway microscope using a × 10 objective. Subsequent automated image acquisition was performed with a × 10 objective using the Molecular Devices ImageXpress Micro imaging system or Yokogawa CV7000. Four (2 × 2) to nine (3 × 3) images were acquired from each well for each fluorescence channel depending on the instrument, typically resulting in the counting of more than 3,000 cells in the control sample. High-resolution images were acquired on the inverted microscopes Zeiss LSM 510 Meta, LSM 780 and Leica SP8 for confocal imaging or Deltavision OMX for structured illumination super-resolution microscopy.
Image analysis. Images were processed in Cell Profiler 3.0.0 to identify areas of M1, NP and LAMP1 signal and to measure the intensity and shape parameters of these objects for colocalization analysis. Briefly, images were median filtered to remove noise, and objects were identified in the M1, NP and LAMP1 channels using an adaptive Otsu thresholding method. The M1 and NP objects were masked by the identified LAMP1 objects to create images showing M1 or NP signals from within or outside LAMP1-positive regions. The intensity, shape and location of these objects were then measured. To identify individual cells, the signals from the M1, NP and LAMP1 channels were added together and smoothed with a Gaussian filter creating a smoothed integrated intensity image of all of the three signals. The Hoechst-stained cell nuclei were then identified as objects and used as the seed points to distinguish cell boundaries using the previously created smoothed integrated intensity image. Measurement of M1 and NP object intensities was then made inside and outside the nuclei area. The individual identified M1 and NP objects were then combined for each image to create a mask of all M1 and/or NP signal areas inside or outside the LAMP1 signal areas, and then these were dilated by 2 pixels. Colocalization analysis (rank weighted) was then performed using the raw M1 and NP images masked by either of these masks.
Phenotypic analysis of the M1-uncoating data set was performed by supervised machine learning software, the Advanced Cell Classifier 25 . Confocal images for analysis were acquired using a × 63 oil (NA: 1.40) objective at 1,024 × 1,024 pixels per image with a Leica SP8 microscope.
Statistical analysis. Data are represented as the mean ± s.d. For all analyses, multiple independent experiments (n ≥ 3) were carried out. Statistical analysis was performed using Prism 7 (GraphPAD Software Inc.) software.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding author upon request. Atomic coordinates and structure factors of G18A M1-N have been deposited in the Protein Data Bank under accession code 6I3H. 
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